BiotechTube
ARTBIO

ARTBIO

Oslo, Norway· Est.

ARTBIO is pioneering a holistic approach to Alpha Radioligand Therapy (ART), combining a differentiated pipeline with proprietary isotope production and manufacturing capabilities. Founded in 2021 by the inventors of the first-ever metabolically targeted alpha therapy (Xofigo), the company is advancing multiple programs, with its lead candidate AB001 now in Phase 1/2 clinical trials for prostate cancer. Backed by a strong syndicate of top-tier life science investors, ARTBIO aims to unlock the superior efficacy and safety profile of alpha-emitting radioligands to treat a range of solid tumors.

artbio.com

Private Company

Total funding raised: $113M

AI Company Overview

ARTBIO is pioneering a holistic approach to Alpha Radioligand Therapy (ART), combining a differentiated pipeline with proprietary isotope production and manufacturing capabilities. Founded in 2021 by the inventors of the first-ever metabolically targeted alpha therapy (Xofigo), the company is advancing multiple programs, with its lead candidate AB001 now in Phase 1/2 clinical trials for prostate cancer. Backed by a strong syndicate of top-tier life science investors, ARTBIO aims to unlock the superior efficacy and safety profile of alpha-emitting radioligands to treat a range of solid tumors.

Oncology

Technology Platform

A proprietary, integrated platform for Alpha Radioligand Therapy (ART) combining targeted drug discovery, the AlphaDirect™ system for producing the alpha-emitting isotope Lead-212 (Pb-212), and a specialized manufacturing ecosystem.

Funding History

2
Total raised:$113M
Seed$90M
Series A$23M

Opportunities

The alpha radioligand therapy market represents a high-growth frontier in oncology with multi-billion dollar potential across prostate, lung, pancreatic, and breast cancers.
ARTBIO's vertical integration model, controlling the Pb-212 isotope supply, positions it to capture value across the development and supply chain.
Successful clinical validation could make it a key partner or acquisition target for large pharma seeking alpha therapy capabilities.

Risk Factors

Key risks include clinical failure of lead candidate AB001, technical challenges in scaling proprietary isotope production and manufacturing, intense competition from well-funded rivals, evolving regulatory pathways for novel alpha therapies, and the ongoing need to raise significant capital in a challenging biotech funding environment.

Competitive Landscape

ARTBIO competes with Novartis (beta therapies), and alpha therapy developers like Fusion/AstraZeneca and RayzeBio/BMS. Its differentiation lies in its founders' proven alpha therapy expertise, a focused vertical strategy integrating Pb-212 production (AlphaDirect™) with drug development, and a pipeline targeting high-need solid tumors beyond prostate cancer.

More companies in Radiopharmaceuticals →More companies in Norway →